Volume 18, Issue 5 (May 2020)                   IJRM 2020, 18(5): 339-346 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Dehghani Firoozabadi A, Dehghani Firoozabadi R, Eftekhar M, Tabatabaei Bafghi A S, Shamsi F. Maternal and neonatal outcomes among pregnant women with different polycystic ovary syndrome phenotypes: A cross-sectional study. IJRM 2020; 18 (5) :339-346
URL: http://ijrm.ir/article-1-1544-en.html
1- Shahid Sadougui Hospital, Shahid Sadougui University of Medical Sciences, and Health Services, Yazd, Iran. , akramsadatdehghani@gmail.com
2- Research and Clinical Centre for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadougui University of Medical Sciences and Health Services, Yazd, Iran.
3- Research and Clinical Centre for Infertility, Yazd Reproductive Sciences Institute, Shahid Sadougui University of Medical Sciences and Health Services, Yazd, Iran. Abortion Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
4- Shahid Sadougui Hospital, Shahid Sadougui University of Medical Sciences, and Health Services, Yazd, Iran.
Full-Text [PDF 272 kb]   (666 Downloads)     |   Abstract (HTML)  (2429 Views)
Full-Text:   (407 Views)
 
  1. Introduction
Pregnancy is a process associated with various metabolic and hormonal changes, and the onset of polycystic ovary syndrome (PCOS) can affect this process (1). According to the World Health Organization (2012), women with PCOS are at risk of prenatal complications during pregnancy as well as most pregnancy pathologies, including gestational diabetes mellitus, glucose tolerance disorders, pregnancy-induced hypertension, preeclampsia, fetal growth restriction, preterm delivery, and small for gestational age (2). Previous studies have also reported an increased risk of morbidity and hospitalization in the neonatal intensive care unit in pregnant women with PCOS (3, 4). Some reports have suggested an increase in the incidence of spontaneous abortion and preterm delivery for these women compared with healthy pregnant women (1, 5-8). Due to the importance of pregnancy in these women, especially those with infertility, as well as their phenotypic differences and the limited information available on their pregnancy outcomes, this study was designed to evaluate and compare the maternal and neonatal outcomes among pregnant women with different PCOS phenotypes.
 
  1. Materials and Methods
This cross-sectional study was performed on 200 pregnant women under 40 yr old with a history of PCOS according to the ESHRE/ASRM criteria (Rotterdam) (9) who were referred to the obstetrics and gynecology department of Shahid Sadoughi Hospital, Yazd, Iran, between 2017 and 2018.
The exclusion criteria included uterine abnormalities, other causes of hyperandrogenism such as congenital adrenal hyperplasia; malignant ovarian tumors; androgen-secreting tumors; Cushing disease; hyperprolactinemia; chronic diseases such as lupus, kidney, and liver disease; diabetes mellitus; and cigarette, drug, and alcohol use.
Based on the Rotterdam criteria (10), the participants were categorized into four PCOS phenotype groups from the beginning of the prenatal period to delivery:
Type A: Having symptoms of hyperandrogenism, chronic ovulation, and polycystic ovaries
Type B: Having symptoms of hyperandrogenism and chronic anovulation
Type C: Having symptoms of hyperandrogenism and polycystic ovaries
Type D: Having symptoms of chronic ovulation and polycystic ovaries
The participants 'basic characteristics, e.g., age, gravidity, parity, history of abortion and infertility, occupation, history of surgery, use of assisted reproductive techniques, and gestational age, also their maternal outcomes, e.g., gestational diabetes mellitus and hypertension, premature rupture of membranes, preterm labor, small for gestational age, intrauterine growth restriction, intrauterine fetal death, preeclampsia, abortion, amniotic fluid disorders, delivery method, and cause of cesarean section, were recorded. Neonatal information, including weight, neonatal recovery, 5-min Apgar score, neonatal icter, the need for admission, the cause of hospitalization, and the infant mortality rate were recorded in a neonatal complications questionnaire.
 
  1. 1. Ethical consideration
The Ethics Committee of the Shahid Sadoughi University of Medical Sciences, Yazd, Iran, approved the proposal of this research (Code: IR.SSU.MEDICINE.REC.1397.114). Written informed consent was obtained from all participants.
 
  1. 2. Statistical analysis
Considering a 95% confidence interval, a power of 80%, the frequency of phenotype B (16%) in the participants as the lowest frequency, and a 10% error, a sample size of 200 was determined using the following formula:
 

 
All data were analyzed using the Statistical Package for the Social Sciences (SPSS) software (SPSS Inc., Chicago, Illinois, U.S.A), version 17.0.  For the quantitative and qualitative variables, the mean ± standard deviation and the frequency and rate, respectively, were measured and investigated via the Pearson correlation coefficient and Spearman's correlation coefficient tests. A p-value <0.05 was considered significant.
 
  1. Results
In this study, 200 pregnant women with PCOS were studied into four phenotype groups (A-D). Two participants from group D were excluded due to unintended pregnancy and the use of abortion induction. Thus, the final study population consisted of 198 pregnant women with a mean age of 29.2 ± 7.7 year. Group D with 37% and group B with 14% had the highest and lowest frequencies, respectively (Table I).
The participants’ demographic characteristics are presented in Table II. There was no difference in maternal age (p = 0.32) among the four groups. In group A, the history of abortion (48.9%) and infertility (51.1%) was higher than in the other groups; this difference was significant for the infertility history (p = 0.007) (Table II). The miscarriage rate did not differ statistically in study groups. 37 pregnancies resulted in miscarriage. Maternal outcomes was examined only in cases of ongoing pregnancy.
Gestational diabetes mellitus (GDM) was evaluated via two methods: fasting blood sugar (FBS) measurement and an oral glucose tolerance test (OGTT). Our results showed that the rate of GDM was significantly different among the four groups. In addition, group A had a higher abnormal OGTT than the other groups. The highest GDM was associated with phenotype A and the lowest with phenotype D. The FBS comparison among the study groups showed a statistically significant difference between groups (p = 0.035).
Groups B (36.8%) and A (28.57%) had the highest blood pressure levels among the groups (p = 0.001), whereas group C had the lowest level of gestational hypertension (0%). The groups did not differ significantly in terms of preeclampsia (p = 0.08); however, the rate of preeclampsia was higher in groups B and A than in the other groups. The groups were similar regarding the other maternal outcomes, including amniotic fluid, abortion, perinatal outcomes, term, and preterm deliveries, delivery type, and pregnancy termination method. One case of stillbirth was observed in group A, and, overall, the rate of cesarean section in all groups was higher than normal vaginal delivery (Table III).
11 cases of multiple pregnancies were reported that did not differ statistically between groups (TableII). Neonatal outcome was evaluted only on single pregnancies. According to the obtained results, there was no significant difference in the neonatal outcomes among the groups, including the 5-min Apgar score, birth weight, neonatal icter, and frequency of anomalies in newborns (Table IV).




 4. Discussion
In this study, the maternal and neonatal outcomes of different PCOS phenotypes were compared. According to our results, phenotype D (37%) and phenotype B (14%) had the highest and lowest frequencies in the study population, respectively. However, Vaggopoulos and colleagues, in a study on 266 women with PCOS showed that phenotype A was the most frequent (11). Also, Baldani and co-workers obtained similar results in Croatia (12).
In the current research, the abortion rate in phenotypes B and A was higher than in the other phenotypes, but this difference was not statistically significant. According to previous studies, the risk of abortion in women with PCOS is three times higher than in healthy pregnant women (13). Similarly, Palomba and colleagues  demonstrated that the abortion rate in phenotype A is significantly higher than in other phenotypes (14). However, Jakubowicz et al. did not report any differences among the PCOS phenotypes regarding the abortion rate (15). Perhaps it would be possible to achieve more reliable results on the abortion rate in these patients with a higher sample size of different PCOS phenotypes.
Our results also showed that the rate of GDM in women with PCOS significantly differed among the four phenotypic groups, and the highest GDM level was observed in group A. According to the logistic regression analysis, phenotypes A and B had a higher chance of having a higher mean of fasting blood glucose, OGTT, and GDM compared with phenotypes C and D. In Palomba and co-workers' study, GDM was more frequent in phenotypes A and C (14), whereas, , another in 2015 showed that the incidence of GDM in phenotypes A and B was higher than in the other phenotypes (16).
Furthermore, our study results showed that phenotypes B and A had the highest levels of pregnancy-induced hypertension. A previous study demonstrated that the incidence of maternal and neonatal complications in pregnant women with PCOS was higher than in the control group, especially in the phenotypes with oligo-menorrhea and hyperandrogenism. Also, pregnancy-induced hypertension in phenotypes A and B was reported more often than in other phenotypes (17). Moreover, Kollman and colleagues divided PCOS phenotypes into oligo-ovulatory (A, B) and ovulatory (C, D) groups and reported more pregnancy-induced hypertension in groups A and B compared with the other two groups (16).
In the present study, one intrauterine fatal death was observed in group A, which was not statistically different from the other groups. In normal pregnancies, this rate is predicted by mortality in the uterus. Our results were consistent with other studies (18), which reported that PCOS phenotypes have no effect on stillbirths.
another study in 2013 reported that maternal complications such as preeclampsia in pregnant women with PCOS are significantly higher than in healthy pregnant women (19). In Palomba’s study, the incidence of preeclampsia was highest in phenotypes A and B (20). According to Kollmann and others' results, the incidence of preeclampsia in oligo-ovulatory phenotypes is significantly higher than in others (16). In the current research, the incidence of preeclampsia in phenotypes B and A was highest; but, no significant difference regarding preeclampsia was observed among the studied groups. In the logistic regression test, phenotype B had a higher chance of preeclampsia. There were no differences in the other adverse outcomes of pregnancy such as amniotic fluid disorders, premature rupture of membranes, adverse perinatal outcomes, and preterm deliveries between PCOS phenotypic groups, which was consistent with Kollmann and Palomba’s studies (16, 17). Moreover, no significant difference was found in the neonatal outcomes investigated among the different phenotypes of PCOS, including the 5-min Apgar score, birthweight, neonatal anomalies, and NICU admission. similar to Kollmann et al. results (16).

 5.Conclusion
Considering the higher risk of GDM and pregnancy-induced hypertension in PCOS phenotypes A and B, women with these phenotypes require more precise prenatal care.
 
Acknowledgements
This research is part of the M.D dissertation of Akramsadat Dehghani Firoozabadi which has been financially supported by Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
 
Conflict of Interest
The authors declared that there is no conflict of interest.
 
 
Type of Study: Original Article | Subject: Fertility & Infertility

References
1. Homburg R. Pregnancy complications in PCOS. Best Practice & Research Clinical Endocrinology & Metabolism 2006; 20: 281-292. [DOI:10.1016/j.beem.2006.03.009] [PMID]
2. Ghazeeri GS, Nassar AH, Younes Z, Awwad JT. Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. Acta Obstet Gynecol Scand 2012; 91: 658-678. [DOI:10.1111/j.1600-0412.2012.01385.x] [PMID]
3. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999; 84: 1897-1899. [DOI:10.1210/jcem.84.6.5803] [PMID]
4. Bruce-Jones W, Zolese G, White P. Polycystic ovary syndrome and psychiatric morbidity. J Psychosom Obstet Gynecol 1993; 14: 111-116. [DOI:10.3109/01674829309084434] [PMID]
5. Bagegni N, Blaine J, Van Voorhis BJ, Dokras A. Risk of early & late obstetric complications in women with IVF-conceived pregnancies and polycystic ovary syndrome (PCOS). Proceed Obstet Gynecol 2010; 1:1-10. [DOI:10.17077/2154-4751.1050]
6. Galazis N, Docheva N, Nicolaides KH, Atiomo W. Proteomic biomarkers of preterm birth risk in women with polycystic ovary syndrome (PCOS): a systematic review and biomarker database integration. PloS One 2013; 8: e53801. [DOI:10.1371/journal.pone.0053801] [PMID] [PMCID]
7. Nikbakht R, Zargar M, Barekati Z, Mohammad Jafari R, Shahbazian N, Barati M. Adverse pregnancy and neonatal outcomes in polycystic ovary syndrome women. Tehran Univ Med J 2016; 73: 827-831.
8. Wang JX, Davies MJ, Norman RJ. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 2001; 16: 2606-2609. [DOI:10.1093/humrep/16.12.2606] [PMID]
9. Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000; 15: 24-28. [DOI:10.1093/humrep/15.1.24] [PMID]
10. Moran LJ, Norman RJ, Teede HJ. Metabolic risk in PCOS: phenotype and adiposity impact. Trends in Endocrinology and Metabolism 2015; 26: 136-143. [DOI:10.1016/j.tem.2014.12.003] [PMID]
11. Vaggopoulos V, Trakakis E, Chrelias C, Panagopoulos P, Basios G, Makridima S, et al. Comparing classic and newer phenotypes in Greek PCOS women: the prevalence of metabolic syndrome and their association with insulin resistance. J Endocrinol Invest 2013; 36: 478-484.
12. Baldani DP, Škrgatić L, Goldštajn MS, Vrčić H, Čanić T, Strelec M. Clinical, hormonal and metabolic characteristics of polycystic ovary syndrome among obese and nonobese women in the Croatian population. Coll Antropol 2013; 37: 465-470.
13. Winter E, Wang J, Davies MJ, Norman R. Early pregnancy loss following assisted reproductive technology treatment. Hum Reprod 2002; 17: 3220-3223. [DOI:10.1093/humrep/17.12.3220] [PMID]
14. Palomba S, Falbo A, Orio FJr, Zullo F. Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Fertil Steril 2009; 92: 1646-1658. [DOI:10.1016/j.fertnstert.2008.08.087] [PMID]
15. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 524-529. [DOI:10.1210/jcem.87.2.8207] [PMID]
16. Kollmann M, Klaritsch P, Martins WP, Guenther F, Schneider V, Herzog SA, et al. Maternal and neonatal outcomes in pregnant women with PCOS: comparison of different diagnostic definitions. Hum Reprod 2015; 30: 2396-2403. [DOI:10.1093/humrep/dev187] [PMID]
17. Palomba S, Falbo A, Russo T, Tolino A, Orio F, Zullo F. Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes. Fertil Steril 2010; 94: 1805-1811. [DOI:10.1016/j.fertnstert.2009.10.043] [PMID]
18. Roos N, Kieler H, Sahlin L, Ekman-Ordeberg G, Falconer H, Stephansson O. Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study. BMJ 2011; 343: d6309. [DOI:10.1136/bmj.d6309] [PMID] [PMCID]
19. Qin JZ, Pang LH, Li MJ, Fan XJ, Huang RD, Chen HY. Obstetric complications in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod Biol Endocrinol 2013; 11: 56. [DOI:10.1186/1477-7827-11-56] [PMID] [PMCID]
20. Palomba S, De Wilde MA, Falbo A, Koster MP, La Sala GB, Fauser BC. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update 2015; 21: 575-592. [DOI:10.1093/humupd/dmv029] [PMID]

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb